99 related articles for article (PubMed ID: 20685676)
1. Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.
De Caterina R; Connolly SJ; Pogue J; Chrolavicius S; Budaj A; Morais J; Renda G; Yusuf S;
Eur Heart J; 2010 Sep; 31(17):2133-40. PubMed ID: 20685676
[TBL] [Abstract][Full Text] [Related]
2. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
; Connolly S; Pogue J; Hart R; Pfeffer M; Hohnloser S; Chrolavicius S; Pfeffer M; Hohnloser S; Yusuf S
Lancet; 2006 Jun; 367(9526):1903-12. PubMed ID: 16765759
[TBL] [Abstract][Full Text] [Related]
3. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
Connolly SJ; Eikelboom JW; Ng J; Hirsh J; Yusuf S; Pogue J; de Caterina R; Hohnloser S; Hart RG;
Ann Intern Med; 2011 Nov; 155(9):579-86. PubMed ID: 22041946
[TBL] [Abstract][Full Text] [Related]
4. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
Lamberts M; Gislason GH; Olesen JB; Kristensen SL; Schjerning Olsen AM; Mikkelsen A; Christensen CB; Lip GY; Køber L; Torp-Pedersen C; Hansen ML
J Am Coll Cardiol; 2013 Sep; 62(11):981-9. PubMed ID: 23747760
[TBL] [Abstract][Full Text] [Related]
5. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.
Hohnloser SH; Pajitnev D; Pogue J; Healey JS; Pfeffer MA; Yusuf S; Connolly SJ;
J Am Coll Cardiol; 2007 Nov; 50(22):2156-61. PubMed ID: 18036454
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A]).
Perera KS; Pearce LA; Sharma M; Benavente O; Connolly SJ; Hart RG;
Am J Cardiol; 2018 Mar; 121(5):584-589. PubMed ID: 29291887
[TBL] [Abstract][Full Text] [Related]
8. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project.
Lip GY; Clementy N; Pericart L; Banerjee A; Fauchier L
Stroke; 2015 Jan; 46(1):143-50. PubMed ID: 25424474
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
[TBL] [Abstract][Full Text] [Related]
10. Clopidogrel plus aspirin vs oral anticoagulation for atrial fibrillation: the ACTIVE W trial.
DeSilvey DL
Am J Geriatr Cardiol; 2006; 15(5):326-7. PubMed ID: 16957455
[No Abstract] [Full Text] [Related]
11. Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
Sandhu RK; Hohnloser SH; Pfeffer MA; Yuan F; Hart RG; Yusuf S; Connolly SJ; McAlister FA; Healey JS
Stroke; 2015 Mar; 46(3):667-72. PubMed ID: 25628308
[TBL] [Abstract][Full Text] [Related]
12. [Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
Meinertz T
Internist (Berl); 2007 Aug; 48(8):874-5. PubMed ID: 17628764
[No Abstract] [Full Text] [Related]
13. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events.
; ; Connolly S; Yusuf S; Budaj A; Camm J; Chrolavicius S; Commerford PJ; Flather M; Fox KA; Hart R; Hohnloser S; Joyner C; Pfeffer M; Anand I; Arthur H; Avezum A; Bethala-Sithya M; Blumenthal M; Ceremuzynski L; De Caterina R; Diaz R; Flaker G; Frangin G; Franzosi MG; Gaudin C; Golitsyn S; Goldhaber S; Granger C; Halon D; Hermosillo A; Hunt D; Jansky P; Karatzas N; Keltai M; Lanas F; Lau CP; Le Heuzey JY; Lewis BS; Morais J; Morillo C; Oto A; Paolasso E; Peters RJ; Pfisterer M; Piegas L; Pipillis T; Proste C; Sitkei E; Swedberg K; Synhorst D; Talajic M; Trégou V; Valentin V; van Mieghem W; Weintraub W; Varigos J
Am Heart J; 2006 Jun; 151(6):1187-93. PubMed ID: 16781218
[TBL] [Abstract][Full Text] [Related]
14. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).
Healey JS; Hart RG; Pogue J; Pfeffer MA; Hohnloser SH; De Caterina R; Flaker G; Yusuf S; Connolly SJ
Stroke; 2008 May; 39(5):1482-6. PubMed ID: 18323500
[TBL] [Abstract][Full Text] [Related]
15. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
Diener HC; Sacco R; Yusuf S; ;
Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
[TBL] [Abstract][Full Text] [Related]
16. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey [NASIS]).
Schwammenthal Y; Bornstein N; Schwammenthal E; Schwartz R; Goldbourt U; Tsabari R; Koton S; Grossman E; Tanne D
Am J Cardiol; 2010 Feb; 105(3):411-6. PubMed ID: 20102959
[TBL] [Abstract][Full Text] [Related]
17. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
[TBL] [Abstract][Full Text] [Related]
18. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.
Hart RG; Bhatt DL; Hacke W; Fox KA; Hankey GJ; Berger PB; Hu T; Topol EJ;
Cerebrovasc Dis; 2008; 25(4):344-7. PubMed ID: 18303254
[TBL] [Abstract][Full Text] [Related]
19. Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.
Horie N; Kaminogo M; Izumo T; Hayashi K; Tsujino A; Nagata I
Neurol Res; 2015 Jul; 37(7):619-23. PubMed ID: 25798683
[TBL] [Abstract][Full Text] [Related]
20. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial.
Flaker GC; Eikelboom JW; Shestakovska O; Connolly SJ; Kaatz S; Budaj A; Husted S; Yusuf S; Lip GY; Hart RG
Stroke; 2012 Dec; 43(12):3291-7. PubMed ID: 23033347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
